US FDA again postpones verdict on MannKind's inhaled insulin
This article was originally published in Scrip
Executive Summary
Analysts Tuesday were scratching their heads about why the US FDA delayed by four weeks its decision on whether to permit MannKind to market its inhaled diabetes drug Afrezza (insulin human rDNA origin).